MedTrace Logo

Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients

NCT03895762 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 143

Last updated 2022-05-05

No results posted yet for this study

Summary

The purpose of this observational study is:

To observe the efficacy, safety, and tolerability of Abstral ODT for the alleviation of breakthrough cancer pain in Korean patients with various cancers in real-world clinical settings and supplement and expand the previous cross-sectional survey results.

Conditions

  • Breakthrough Cancer Pain

Interventions

DRUG

Abstral Oral Disintegrating Tablet (ODT)

Opioid(Fentanyl)

Sponsors & Collaborators

  • A.Menarini Asia-Pacific Holdings Pte Ltd

    lead INDUSTRY

Principal Investigators

  • Jin-Seok Ahn · Samsung Medical Center

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-04
Primary Completion
2019-06-28
Completion
2019-06-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03895762 on ClinicalTrials.gov